Background/Aims: Rimonabant is a cannabinoid CB1 receptor antagonist. Other CB1 antagonists have biphasic effects on blood glucose levels following acute administration. We therefore tested the effects of rimonabant on glucose tolerance following acute administration. Methods: We tested the effects of oral and intracerebroventricular administration of rimonabant on blood glucose and gastrointestinal transit in mice following oral and intravenous glucose challenge. Results: We found a dose-dependent increase in blood glucose from oral doses of rimonabant of 3 mg/kg and above. WIN55,212-2 (3 mg/kg), a cannabinoid receptor agonist, did not influence blood glucose in the presence or absence of rimonabant. Rimonabant did not induce release of glucose from isolated rat hepatocytes or modify serum insulin concentration in mice. Intracerebroventricular administration of rimonabant caused increases in blood glucose and gastrointestinal transit, suggesting a central nervous system site of action. Increases in blood glucose by rimonabant were partially blocked by the dopamine receptor antagonist haloperidol and significantly blocked by the 5-hydroxytryptophan (5-HT) depleting agent p-CPA and the 5-HT3 receptor antagonist ondansetron. Conclusions: Rimonabant causes a dose-dependent increase in glucose profile upon glucose challenge partially mediated by the central nervous system control of gastrointestinal carbohydrate absorption through pathways that are modulated by both 5-HT and dopamine.

Keywords:
Cannabinoids, Dopamine, 5-Hydroxytryptophan, Glucose tolerance, Insulin, Rimonabant, WIN55,212-2
1.
Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D: SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350:240–244.
2.
Pertwee RG: Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006;147:S163–S171.
3.
McLaughlin PJ, Winston K, Swezey L, Wisniecki A, Aberman J, Tardif DJ, Betz AJ, Ishiwari K, Makriyannis A, Salamone JD: The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 2003;14:583.
4.
Gadde KM: Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction. Curr Drug Targets Cardiovasc Hematol Disord 2005;5:549–556.
5.
Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A, Martin BR: CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 2005;145:293–300.
6.
Després JP, Golay A, Sjostrom L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121.
7.
Bermúdez-Silva FJ, Serrano A, Diaz-Molina FJ, Sánchez Vera I, Juan-Pico P, Nadal A, Fuentes E, Rodríguez de Fonseca F: Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006;531:282–284.
8.
Bermudez-Silva FJ, Sanchez-Vera I, Suárez J, Serrano A, Fuentes E, Juan-Pico P, Nadal A, Rodríguez de Fonseca F: Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 2007;565:207–211.
9.
Izzo AA, Sharkey KA: Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010;126:21–38.
10.
Horowitz M, Edelbroek MAL, Wishart JM, Straathof JW: Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993;36:857–862.
11.
Darmani NA, Janoyan JJ, Kumar N, Crim JL: Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 2003;75:777–787.
12.
Griebel G, Stemmelin J, Scatton B: Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005;57:261–267.
13.
Haley TJ, McCormick WG: Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 1957;12:12.
14.
Pharmacopoeia US: United States Pharmacopoeia and National Formulary (USP 34-NF 29). Rockville, United States Pharmacopoeia Convention, 2011, vol 2, pp 2977–2979.
15.
Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez de Fonseca F: A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002;22:9612.
16.
Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME: Atypical responsiveness of the orphan receptor gpr55 to cannabinoid ligands. J Biol Chem 2009;284:29817–29827.
17.
Romero-Zerbo SY, Rafacho A, Diaz-Arteaga A, Suarez J, Quesada I, Imbernon M, Ross RA, Dieguez C, Rodriguez de Fonseca F, Nogueiras R, Nadal A, Bermudez-Silva FJ: A role for the putative cannabinoid receptor gpr55 in the islets of langerhans. J Endocrinol 2011;211:177–185.
18.
Pegorini S, Zani A, Braida D, Guerini-Rocco C, Sala M: Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection. Br J Pharmacol 2006;147:552–559.
19.
Akiba Y, Kato S, Katsube K, Nakamura M, Takeuchi K, Ishii H, Hibi T: Transient receptor potential vanilloid subfamily 1 expressed in pancreatic islet beta cells modulates insulin secretion in rats. Biochem Biophys Res Commun 2004;321:219–225.
20.
Fong T, Shearman L, Stribling D, Shu J, Lao J, Huang CRR, Xiao J, Shen CP, Tyszkiewicz J, Strack A: Pharmacological efficacy and safety profile of taranabant in preclinical species. Drug Dev Res 2009;70:349–362.
21.
Juan-Picó P, Fuentes E, Javier BS: Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006;39:155–162.
22.
Getty-Kaushik L, Richard AMT, Deeney JT, Krawczyk S, Shirihai O, Corkey BE: The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets. Obesity 2009;17:1856–1860.
23.
Gin H, Rigalleau V: Post-prandial hyperglycemia. Post-prandial hyperglycemia and diabetes. Diabet Metab 2000;26:265–272.
24.
Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le Fur G, Galiegue S: The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005;19:1567–1569.
25.
Lichtman AH, Cravatt BF: Food for thought: endocannabinoid modulation of lipogenesis. J Clin Invest 2005;115:1130–1133.
26.
Herling AW, Gossel M, Haschke G, Stengelin S, Kuhlmann J, Muller G, Schmoll D, Kramer W: CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab 2007;293:E826.
27.
Schwartz JG, Guan D, Green GM, Phillips WT: Treatment with an oral proteinase inhibitor slows gastric emptying and acutely reduces glucose and insulin levels after a liquid meal in type II diabetic patients. Diabetes Care 1994;17:255.
28.
Jones KL, Horowitz M, Carney BI, Wishart JM, Guha S, Green L: Gastric emptying in early noninsulin-dependent diabetes mellitus. J Nucl Med 1996;37:1643.
29.
Shiroyama K, Moriwaki K, Yuge O: The direct effect of dopamine on glucose release from primary cultured rat hepatocytes. In Vivo 1998;12:527.
30.
Durant S, Coulaud J, Homo-Delarche F: Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action. Rev Diabet Stud 2007;4:185.
31.
Nonogaki K, Iguchi A: Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci 1997;60:797–807.
32.
Hsiao SH, Chung HH, Inui A, Tong YC, Cheng JT: Inhibitory effect of 5-hydroxytryptamine on hyperphagia in mice with genetic overexpression of neuropeptide Y. Neurosci Lett 2006;394:256–258.
33.
Chaouloff F, Laude D, Baudrie V: Ganglionic transmission is a prerequisite for the adrenaline-releasing and hyperglycemic effects of 8-OH-DPAT. Eur J Pharmacol 1990;185:11–18.
34.
Carvalho F, Macedo D, Bandeira I, Maldonado I, Salles L, Azevedo MF, Rocha MA, Fregoneze JB, De Castro-e-Silva E: Central 5-HT3 receptor stimulation by m-CPBG increases blood glucose in rats. Horm Metab Res 2002;34:55–61.
35.
O’Donovan DG, Doran S, Feinle-Bisset C, Jones KL, Meyer JH, Wishart JM, Morris HA, Horowitz M: Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J Clin Endocrinol Metab 2004;89:3431.
36.
Matsuda H, Li Y, Yamahara J, Yoshikawa M: Inhibition of gastric emptying by triterpene saponin, momordin Ic, in mice: roles of blood glucose, capsaicin-sensitive sensory nerves, and central nervous system. J Pharmacol Exp Ther 1999;289:729.
37.
Andrews JM, Rayner CK, Doran S, Hebbard GS, Horowitz M: Physiological changes in blood glucose affect appetite and pyloric motility during intraduodenal lipid infusion. Am J Physiol 1998;275:G797–G804.
38.
Chapman IM, Goble EA, Wittert GA, Morley JE, Horowitz M: Effect of intravenous glucose and euglycemic insulin infusions on short-term appetite and food intake. Am J Physiol 1998;274:R596–R603.
39.
Arneric SP, Chow SA, Long JP, Fischer LJ: Dopamine analog-induced hyperglycemia in rats: involvement of the adrenal medulla and the endocrine pancreas. J Pharmacol Exp Ther 1984;228:551.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.